We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

707 hedge funds and large institutions have $22.6B invested in Alexion Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 262 increasing their positions, 264 reducing their positions, and 70 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 70

1% more capital invested

Capital invested by funds: $22.4B → $22.6B (+$224M)

0% more funds holding

Funds holding: 705 → 707 (+2)

1% less repeat investments, than reductions

Existing positions increased: 262 | Existing positions reduced: 264

13% less call options, than puts

Call options by funds: $275M | Put options by funds: $315M

14% less funds holding in top 10

Funds holding in top 10: 21 → 18 (-3)

Holders
707
Holders Change
+2
Holders Change %
+0.28%
% of All Funds
14.27%
Holding in Top 10
18
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-14.29%
% of All Funds
0.36%
New
75
Increased
262
Reduced
264
Closed
70
Calls
$275M
Puts
$315M
Net Calls
-$40.8M
Net Calls Change
+$31.5M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$306M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$142M
3
Man Group
Man Group
United Kingdom
+$89.1M
4
AL
AJO LP
Pennsylvania
+$86.3M
5
Nomura Holdings
Nomura Holdings
Japan
+$63.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$466M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$346M
3
Ameriprise
Ameriprise
Minnesota
-$101M
4
CNBT
Cornerstone National Bank & Trust
Illinois
-$90.6M
5
HM
HealthCor Management
New York
-$74.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.27B +$306M +2,831,898 +17%
BlackRock
2
BlackRock
New York
$2.07B -$46.2M -428,185 -2%
State Street
3
State Street
Massachusetts
$1.27B +$7.21M +66,854 +0.6%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$1.12B -$346M -3,208,004 -25%
BBA
5
Baker Bros. Advisors
New York
$1B – – –
ClearBridge Investments
6
ClearBridge Investments
New York
$733M -$53M -491,377 -7%
Ameriprise
7
Ameriprise
Minnesota
$584M -$101M -935,750 -16%
Renaissance Technologies
8
Renaissance Technologies
New York
$544M +$30M +278,000 +6%
JP Morgan Chase
9
JP Morgan Chase
New York
$472M +$40.4M +374,895 +10%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$433M -$260K -2,410 -0.1%
LSV Asset Management
11
LSV Asset Management
Illinois
$405M +$4.69M +43,464 +1%
Norges Bank
12
Norges Bank
Norway
$402M -$6.25M -57,898 -2%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$357M -$466M -4,324,105 -58%
Northern Trust
14
Northern Trust
Illinois
$322M -$1.14M -10,553 -0.4%
Swedbank
15
Swedbank
Sweden
$300M -$1.48M -13,687 -0.5%
O
16
OrbiMed
New York
$250M +$3.07M +28,500 +1%
First Trust Advisors
17
First Trust Advisors
Illinois
$245M +$19.3M +178,489 +9%
Bank of America
18
Bank of America
North Carolina
$227M +$5.71M +52,925 +3%
CS
19
Credit Suisse
Switzerland
$225M -$16M -148,259 -7%
AQR Capital Management
20
AQR Capital Management
Connecticut
$214M -$24.1M -223,011 -11%
PAMU
21
Pictet Asset Management (UK)
United Kingdom
$208M -$8.34M -77,280 -4%
Manulife (Manufacturers Life Insurance)
22
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$204M -$3.56M -33,041 -2%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$203M +$10.1M +93,861 +6%
UBS AM
24
UBS AM
Illinois
$182M -$6.52M -60,415 -4%
Janus Henderson Group
25
Janus Henderson Group
United Kingdom
$177M +$142M +1,313,698 +562%
1
2 3 4 5

ALXN Hedge Fund Activity: Q3 2020 in Review

707 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2020, worth a combined $22.6B — up 1% from $22.4B a quarter earlier.

Buyers outnumbered sellers: 75 funds opened new ALXN positions and 70 closed out — a net gain of 5 holders — while 262 added to existing stakes and 264 trimmed.

The largest buyer was Vanguard Group, adding an estimated $306M. The largest seller was T. Rowe Price Associates, cutting an estimated $466M.

  • 707 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2020, up from 705 in Q2 2020.
  • Funds reported $22.6B of Alexion Pharmaceuticals stock for Q3 2020, up 1% quarter-over-quarter.
  • 75 funds opened new Alexion Pharmaceuticals positions in Q3 2020 and 70 closed out, a net change of +5 holders.
  • The largest Alexion Pharmaceuticals buyer in Q3 2020 was Vanguard Group, an estimated $306M added.
  • The largest Alexion Pharmaceuticals seller in Q3 2020 was T. Rowe Price Associates, an estimated $466M sold.

Based on aggregated 13F filings for Q3 2020.